Apotex Launches Generic Semaglutide Injection in Canada

New Diabetes Therapy Expands Access to Affordable GLP-1 Treatment

Apotex has announced the commercial launch of Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada. The once-weekly injectable medicine is approved for adults with type 2 diabetes and is intended to improve blood glucose control when used alongside diet and exercise. The launch strengthens access to lower-cost GLP-1 therapies while expanding treatment options for healthcare providers and patients across the country.

Increasing Availability of Diabetes Medicines

The introduction of Apo-Semaglutide Injection follows Health Canada authorization and makes Apotex one of the first Canadian pharmaceutical companies to commercialize a generic semaglutide product. The therapy is supplied in 2 mg and 4 mg prefilled pen formats, matching commonly used dosage configurations to support convenient weekly administration.

Supporting Affordable Healthcare

The availability of a generic semaglutide is expected to improve patient access by increasing competition within the GLP-1 market. Affordable treatment alternatives can help healthcare systems expand access to diabetes medications while maintaining high standards of quality, safety and efficacy through regulatory approval processes.

Strengthening Diabetes Care

With the global prevalence of type 2 diabetes continuing to rise, accessible treatment options remain an important priority for healthcare providers. Apotex's latest product launch reinforces its commitment to supplying high-quality generic medicines that support long-term diabetes management and improve treatment accessibility for patients across Canada.

Key Features

• Apo-Semaglutide Injection™ for adults with type 2 diabetes

• Generic equivalent of Ozempic® approved in Canada

• Available in 2 mg and 4 mg prefilled pen formats

• Once-weekly administration

• Supports blood glucose management alongside diet and exercise

• Manufactured by Apotex

• Expands access to affordable GLP-1 therapy

• Health Canada approved product

Applications

• Type 2 diabetes management

• Blood glucose control programs

• Endocrinology practice

• Hospital diabetes care

• Outpatient diabetes treatment

• Primary healthcare services

• Chronic disease management

• Pharmaceutical therapy programs

Expanding Access to Diabetes Treatment

As healthcare systems continue seeking effective and affordable therapies for chronic diseases, the introduction of generic GLP-1 medicines represents an important step toward broader patient access. Apotex's Apo-Semaglutide Injection provides healthcare professionals with an additional treatment option while contributing to more accessible diabetes care across Canada.